Literature DB >> 10087733

Malignant ascites in female patients: a seven-year review.

S Wilailak1, V Linasmita, S Srivannaboon.   

Abstract

Malignant ascites is common in various types of advanced cancer. Our objective was to determine the primary site and the clinical characteristics of female patients presenting with malignant ascites as well as evaluating the outcome. The authors carried out a retrospective study of 118 cases of malignant ascites diagnosed from January 1986 to December 1992 in female patients. Of the 118 cases, the primary site of the neoplasms was gynecologic in 65 cases (cervix 4, endometrium 6, ovary 52, fallopian tube 3) = 55.1 per cent, non-gynecologic 29 cases (GI 18, lymphoma 8, breast 2, kidney 1) = 24.6 per cent, and unknown 24 cases = 20.3 per cent. The mean age of patients in the gynecologic, non-gynecologic and unknown primary site was 50.4, 45.5 and 59.3 years respectively. Surgery combined with chemotherapy was the main treatment in the gynecologic group, whereas, supportive and symptomatic management was the main treatment in the unknown primary group. Treatments in non-gynecologic group were supportive and symptomatic, surgery and chemotherapy. Survival was longer in gynecologic than in the nongynecologic and the unknown primary groups. The most common primary site of malignant ascites in females was ovarian cancer. In malignant ascites in females caused by gynecologic neoplasms, the prognosis as measured by survival was better than in the non-gynecologic and the unknown primary groups.

Entities:  

Mesh:

Year:  1999        PMID: 10087733

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  6 in total

1.  Effect of paracentesis on the survival of patients with terminal cancer and ascites: a propensity score-weighted analysis of the East Asian Collaborative Cross-cultural Study to Elucidate the Dying Process.

Authors:  Ken Masuda; Hiroto Ishiki; Naosuke Yokomichi; Takuhiro Yamaguchi; Tetsuya Ito; Hana Takatsu; Koji Amano; Shuji Hiramoto; Toshihiro Yamauchi; Takashi Kawaguchi; Masanori Mori; Yosuke Matsuda; Takashi Yamaguchi
Journal:  Support Care Cancer       Date:  2022-04-21       Impact factor: 3.603

Review 2.  Management of drainage for malignant ascites in gynaecological cancer.

Authors:  Alison Keen; Debbie Fitzgerald; Andrew Bryant; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

3.  Do concomitant ascites influence the effectiveness of palliative surgical management of pleural effusion in patients with malignancies?

Authors:  Jefferson Luiz Gross; Tatiana Guilherme Disanzio; Riad Naim Younes; Fabio José Haddad; Rodrigo Afonso da Silva; Antonio Bomfim Marçal Avertano
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.352

Review 4.  Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.

Authors:  Samar Masoumi Moghaddam; Afshin Amini; David L Morris; Mohammad H Pourgholami
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

5.  Development and validation of the self-completed ascites impact measure to understand patient motivation for requesting a paracentesis.

Authors:  Bruce Crawford; Elizabeth Piault; Walter Gotlieb; Florence Joulain
Journal:  Patient Relat Outcome Meas       Date:  2012-06-21

6.  Management of drainage for malignant ascites in gynaecological cancer.

Authors:  Chumnan Kietpeerakool; Siwanon Rattanakanokchai; Nampet Jampathong; Jatupol Srisomboon; Pisake Lumbiganon
Journal:  Cochrane Database Syst Rev       Date:  2019-12-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.